Pre-made Lemalesomab benchmark antibody (Whole mAb, anti-NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [human] therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Anti-NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [human] therapeutic antibody (Pre-made Lemalesomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lemalesomab is a mouse monoclonal antibody for the diagnosis of inflammatory lesions.[1][2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-886-1mg	1mg	3090
GMP-Bios-INN-886-10mg	10mg	Inquiry
GMP-Bios-INN-886-100mg	100mg	Inquiry
GMP-Bios-INN-886-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lemalesomab Biosimilar, Whole Mab: Anti-Nca-90 (Nonspecific Cross- Reacting Antigens 90Kda Glycoproteins, Granulocyte Cell Antigen) [human] therapeutic antibody
INN Name	Lemalesomab
Target	NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [human]
Format	Whole mAb
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	IgG1 - nd
VD LC	IgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	0
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0